{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:05:16Z","timestamp":1790665516685,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to assess macrophages in tissue biopsy specimens collected before the initiation of induction therapy. Twelve PMBCL patients, including five patients who had disease relapse, were included in the analysis. At a median follow-up time of 32.2\u00a0months, the median progression-free and overall survival durations were not reached. Our findings suggest that a high density of PD-L1<jats:sup>+<\/jats:sup> macrophages is associated with favorable features, such as early disease stage and the absence of B-symptoms, and indicate that a high percentage of PD-L1<jats:sup>+<\/jats:sup> macrophages and high densities of CD30<jats:sup>+<\/jats:sup>PD-L1<jats:sup>+<\/jats:sup> cells and CD30<jats:sup>+<\/jats:sup> cells might be associated with a lower risk of relapse within 12\u00a0months of therapy initiation. Further studies are needed to develop a biomarker signature predictive of treatment response with therapeutic consequences for patients with newly diagnosed PMBCL.<\/jats:p>","DOI":"10.1186\/s40164-023-00396-0","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T11:03:14Z","timestamp":1679310194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma"],"prefix":"10.1186","volume":"12","author":[{"given":"Raphael E.","family":"Steiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Noorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario L.","family":"Marques-Piubelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"17","key":"396_CR1","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, et al. Integrative analysis reveals selective 9p241 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268\u201377.","journal-title":"Blood"},{"issue":"10","key":"396_CR2","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","volume":"118","author":"C Steidl","year":"2011","unstructured":"Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659\u201369.","journal-title":"Blood"},{"issue":"24","key":"396_CR3","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1182\/blood.2019004296","volume":"136","author":"AR Hayden","year":"2020","unstructured":"Hayden AR, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood. 2020;136(24):2803\u201311.","journal-title":"Blood"},{"issue":"15","key":"396_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408\u201316.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"396_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-143171","volume":"136","author":"C Casulo","year":"2020","unstructured":"Casulo C, et al. Describing treatment of primary mediastinal large B cell lymphoma using rigorously defined molecular classification: a retrospective analysis. Blood. 2020;136(Supplement 1):35\u20136.","journal-title":"Blood"},{"issue":"4","key":"396_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cac2.12023","volume":"40","author":"WCC Tan","year":"2020","unstructured":"Tan WCC, et al. Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun. 2020;40(4):135\u201353.","journal-title":"Cancer Commun"},{"issue":"11","key":"396_CR7","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/bloodadvances.2022007104","volume":"6","author":"ML Marques-Piubelli","year":"2022","unstructured":"Marques-Piubelli ML, et al. SIRP\u03b1+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv. 2022;6(11):3286\u201393.","journal-title":"Blood Adv"},{"issue":"5","key":"396_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.pathol.2020.11.004","volume":"53","author":"K Antel","year":"2021","unstructured":"Antel K, et al. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients. Pathology. 2021;53(5):628\u201334.","journal-title":"Pathology"},{"issue":"41","key":"396_CR9","doi-asserted-by":"publisher","first-page":"67333","DOI":"10.18632\/oncotarget.12024","volume":"7","author":"A Romano","year":"2016","unstructured":"Romano A, et al. The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. Oncotarget. 2016;7(41):67333\u201346.","journal-title":"Oncotarget"},{"issue":"34","key":"396_CR10","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019;37(34):3291.","journal-title":"J Clin Oncol"},{"issue":"6","key":"396_CR11","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov N, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021;11(6):1468\u201389.","journal-title":"Cancer Discov"},{"issue":"16","key":"396_CR12","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7589","volume":"40","author":"RE Steiner","year":"2022","unstructured":"Steiner RE, et al. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma. J Clin Oncol. 2022;40(16):7589\u20137589.","journal-title":"J Clin Oncol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00396-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T06:10:02Z","timestamp":1680156602000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00396-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00396-0","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of MD Anderson Cancer Center and conducted (protocol 2020\u20130228) in accordance with our institutional guidelines and the principles of the Declaration of Helsinki. The IRB approved the request of waiver of informed consent and a waiver of authorizations as the study does not involve therapeutic intervention or any type of direct patient contact.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required by IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.E.S.: Research funding: Rafael Pharmaceuticals, BMS, GSK, and Seattle Genetics. E.R.P. has nothing to disclose. F.V. receives research funding from NCI, CRISP Therapeutics, Allogene, Geron corporation and from the Moonshot program at MDACC. L.F. has nothing to disclose. J.R.W. has received research funding from Kite, BMS, Novartis, Genentech, AstraZeneca, Morphosys\/Incyte, ADC Therapeutics, Calithera, Kymera; consulting: Kite, BMS, Novartis, Genentech, AstraZeneca, Morphosys\/Incyte, ADC Therapeutics, Calithera, Merck, Abbvie\/GenMab, SeaGen, MonteRosa, Iksuda. S.S.N. has received research support from Kite\/Gilead, BMS, Cellectis, Poseida, Allogene, Unum Therapeutics, Precision Biosciences, and Adicet Bio; served as Advisory Board Member\/Consultant for Kite\/Gilead, Merck, Novartis, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Legend Biotech, Bluebird Bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma, and Morphosys; has received royalty income from Takeda Pharmaceuticals; has stock options from Longbow Immunotherapy, Inc; and has intellectual property related to cell therapy. P.S. has received research support from Sobi, Astrazeneca Acerta, ADC Therapeutics, ALX Oncology. Advisory board\/consultancy: Hutchinson Medipharma, Roche Genentech, Astrazeneca Acerta, ADC Therapeutics, TG Therapeutics, Kite Gilead, Sobi, Incyte Morphosys. M.R.G. reports research funding from Sanofi, Kite\/Gilead, Abbvie and Allogene; consulting for Abbvie; honoraria from Tessa Therapeutics, Monte Rosa Therapeutics and Daiichi Sankyo; and stock ownership of KDAc Therapeutics. C.R.F. is consultant for Abbvie, Bayer,\u00a0BeiGene, Celgene,\u00a0Denovo\u00a0Biopharma, Foresight Diagnostics, Genentech\/Roche, Genmab,\u00a0Gilead,\u00a0Karyopharm, N-Power Medicine, Pharmacyclics\/Janssen, SeaGen,\u00a0Spectrum, has stock Options with Foresight Diagnostics, N-Power Medicine, has research Funding from 4D,\u00a0Abbvie,\u00a0Acerta,\u00a0Adaptimmune,\u00a0Allogene,\u00a0Amgen, Bayer, Celgene,\u00a0Cellectis EMD,\u00a0Gilead, Genentech\/Roche,\u00a0Guardant,\u00a0Iovance,\u00a0Janssen Pharmaceutical, Kite, Morphosys,\u00a0Nektar,Novartis,\u00a0Pfizer,\u00a0Pharmacyclics,\u00a0Sanofi,\u00a0Takeda,\u00a0TG Therapeutics,\u00a0Xencor,\u00a0Ziopharm,\u00a0Burroughs\u00a0Wellcome\u00a0Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research. L.M.S. has nothing to disclose. I.I.W. has provided consulting or advisory roles for AstraZeneca\/MedImmune, Bayer, Bristol-Myers Squibb, Genentech\/Roche, GlaxoSmithKline, Guardant Health, HTG Molecular Diagnostics, Merck, MSD Oncology, OncoCyte, Jansen, Novartis, Flame Inc, and Pfizer; has received grants and personal fees from Genentech\/Roche, Bristol Myers Squibb, AstraZeneca\/MedImmune, HTG Molecular, Merck, and Guardant Health; has received personal fees from GlaxoSmithKline and Oncocyte, Daiichi-Sankyo, Roche, Astra Zeneca, Regeneron, Sanofi, Pfizer and Bayer; has received research funding to his institution from 4D Molecular Therapeutics, Adaptimmune, Adaptive Biotechnologies, Akoya Biosciences, Amgen, Bayer, EMD Serono, Genentech, Guardant Health, HTG Molecular Diagnostics, Iovance Biotherapeutics, Johnson & Johnson, Karus Therapeutics, MedImmune, Merck, Novartis, OncoPlex Diagnostics, Pfizer, Takeda, and Novartis. S.A. has received research support paid to her institution from Tessa Therapeutics, SeaGen, Merck, Xencor, Chimagen; Advisory committee member: Sanofi, SeaGen, Tessa Therapeutics; Consultancy: Novartis, Myeloid Therapeutics, Servier, Chimagen. R.N. has received honoraria from Incyte for speaker\/preceptorship. F.B.H. has nothing to disclose. M.N. has nothing to disclose. M.L.M-P. has nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}